呼吸道合胞病毒疫苗接种后不良事件与接种差错:美国VAERS数据库2023-2025年分析
基于美国VAERS数据库2023年1月至2025年12月的8365份RSV疫苗接种后不良事件报告,多数为非严重事件。Arexvy®和Abrysvo®报告最多,常见事件包括额外剂量接种和妊娠期暴露;不均衡分析检测到额外剂量、接种于不适宜年龄患者等接种差错的风险信号。
要点
- RSV疫苗接种后不良事件报告以非严重事件为主,Arexvy®和Abrysvo®占绝大多数。
- Arexvy®最常见报告为额外剂量接种和注射部位反应;Abrysvo®最常见为妊娠期暴露和额外剂量接种。
- 两种疫苗均显示额外剂量接种、接种于不适宜年龄患者等接种差错的报告风险信号。
核心结论
- RSV疫苗接种后不良事件报告大多为非严重事件。
- Arexvy®在妊娠期潜在误用及两种疫苗的额外剂量接种提示医护人员教育和疫苗接种记录检索存在缺口。
研究设计与样本
- 研究检索美国疫苗不良事件报告系统(VAERS)2023年1月1日至2025年12月31日RSV疫苗接种后不良事件报告,共8365份。
- 分析报告特征,按疫苗品牌描述最常见不良事件,对Arexvy®和Abrysvo®前15位不良事件和前10位接种差错进行不均衡分析(报告比值比,SAS 9.4)。
主要发现
- 8365份报告中,Arexvy®占68.2%,Abrysvo®占29.9%。
- Arexvy®最常见5种不良事件:额外剂量接种(15.0%)、注射部位疼痛(12.8%)、注射部位红斑(11.3%)、注射部位肿胀(9.0%)、疼痛(9.0%)。
- Abrysvo®最常见5种不良事件:妊娠期暴露(10.6%)、额外剂量接种(9.9%)、头痛(7.7%)、疲劳(7.7%)、注射部位疼痛(7.3%)。
- Arexvy®接种后报告中4.2%(n=244)来自<50岁个体,6.6%(n=375)为妊娠期暴露。
- Arexvy®和Abrysvo®均显示额外剂量接种、接种于不适宜年龄患者等接种差错的显著报告风险信号。
临床怎么用
- 接种前应核对疫苗品牌、适用年龄和妊娠状态,避免不适宜年龄或妊娠期接种。
- 应完善疫苗接种记录检索,减少额外剂量接种差错。
- 应加强医护人员关于RSV疫苗适用人群和禁忌的教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Three respiratory syncytial virus (RSV) vaccines are marketed in the U.S. for use in adults aged ≥18 years: Arexvy® (GSK), Abrysvo® (Pfizer), and mRESVIA® (Moderna), with only Abrysvo® approved for use during pregnancy. This study describes post-marketing adverse event (AE) reports after RSV vaccination and detected reporting risk signals of administration-related errors using the U.S. Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for reports of AE following RSV vaccination during January 1, 2023 - December 31, 2025. We assessed the characteristics of these reports and described the most commonly reported AEs by RSV vaccine brand. The top 15 most frequently reported AEs and top 10 most frequently reported vaccine administration errors were examined for Arexvy® and Abrysvo®. Disproportionality analyses (reporting odds ratio) were conducted to detect disproportionate reporting risk signals of vaccine administration errors (SAS version 9.4). RESULTS: During the study period, VAERS received 8365 AE reports following RSV vaccination; most were after Arexvy® (68.2%) and Abrysvo® (29.9%). The 5 most frequently reported AEs for Arexvy® were extra dose administered (15.0%), injection site pain (12.8%), injection site erythema (11.3%), injection site swelling (9.0%), and pain (9.0%); while for Abrysvo®, they included exposure during pregnancy (10.6%), extra dose administered (9.9%), headache (7.7%), fatigue (7.7%) and injection site pain (7.3%). Although not recommended for use during the study period, 4.2% (n = 244) of reports after Arexvy® vaccination were from individuals <50 years old; 6.6% (n = 375) were exposure during pregnancy. Both Arexvy® and Abrysvo® exhibited significant signals for vaccine administration errors such as extra dose administered and product administered to patient of inappropriate age. CONCLUSIONS: Most AE reports following RSV vaccination were non-serious. The potential misuse of Arexvy® during pregnancy and excess dose for both Arexvy® and Abrysvo® highlight potential gaps in healthcare provider education and vaccine record retrieval.
引用
- Ezeja L, Ezeala OM, Westrick SC, et al. Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025. Vaccine. 2026. PMID: 42372626. doi:10.1016/j.vaccine.2026.128896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。